JPRN-UMIN000028065
Completed
N/A
Predictive Value of Genetic Analysis for Pathological Complete Response to Preoperative Treatment in HER2-Positive HR-Negative Early Breast Cancer - PASSION trial
ConditionsHER2-positive HR-negative breast cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- HER2-positive HR-negative breast cancer
- Sponsor
- Japan Agency for Medical Research and development
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Active other malignancies
- •2\. Bilateral breast cance
- •3\. Multicentric tumors
- •4\. History of congestive heart failure or myocardial infarction, arrhythmia or heart valvular disease requiring treatment
- •5\. Clinically significant infection
- •6\. Pregnant or breast\-feeding women, women of childbearing potential
- •7\. Diabetes uncontrolled or requiring insulin
- •8\. Systemic sclerosis or systemic lupus erythematosus
- •9\. Systemic use of steroids or immunosuppressive agents
- •10\. Unsuitable mental status for participation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Research on genetic profiling and its clinical significance using clinical specimens from cancer patientsJPRN-UMIN000049066ational Cancer Center Hospital East Department of Gastroenterology700
Completed
N/A
GENetic and clinical Predictors Of treatment response in DepressioISRCTN31345163Medical Research Council (UK)887
Completed
Phase 3
Validation of genetic diagnosis to predict sensitivity in primary systemic chemotherapy with paclitaxel in women with breast cancerBreast cancerJPRN-C000000413Cancer Institute Hospital, Japanese Foundation for Cancer Research109
Recruiting
N/A
Genetic analysis of prognosis-related factors in gliomas: methylation of MGMT, LOH of 1p/19q, and mutation of IDH1/2.GliomaJPRN-UMIN000003196Yokohama City University of Medicine100
Recruiting
Phase 4
Whether medical treatment based on genetic testing has any impact of the bleeding and treatment costs when compared to usual care without genetic testingCTRI/2019/06/019648Dr Akash Shukla